title: Pharmacokinetics of beclomethasone 17-monopropionate from a beclomethasone dipropionate extrafine aerosol in adults with asthma.
abstract: OBJECTIVE
  The objectives of this study were to test the dose and strength proportionalities of beclomethasone dipropionate (BDP) delivered from two strengths of a pressurized extrafine solution formulation.
  
  
  METHODS
  Thirty adults with mild, stable asthma, aged between 18 years and 70 years, completed the study; written informed consent was obtained from all patients. Each patient received, according to a randomized four-period crossover design, 100 microg BDP as two inhalations from 50-microg/actuation strength, 100 microg BDP as one inhalation from 100-microg/actuation strength, 400 microg BDP as eight inhalations from the 50-microg/actuation strength, and 400 microg BDP as four inhalations from the 100-microg/actuation strength. Patients self-administered all inhalations at the same time of day during the study. Blood samples were collected for 12 h during each period to assay for the presence of BDP and metabolites. The log-transformed pharmacokinetic data were compared for proportionality equivalence using a confidence-interval approach.
  
  
  RESULTS
  Almost all the BDP-derived material in the plasma was the active metabolite beclomethasone 17-monopropionate (17-BMP). Due to low levels, neither elimination half-life ( t(1/2)) nor the area under the plasma concentration-time curve (AUC) for 17-BMP could be calculated for the 100-microg BDP doses. Dose proportionality of the 100-microg and 400-microg BDP doses, using 17-BMP maximum plasma concentration (C(max)) was demonstrated for each strength. Strength proportionality of the 50-microg and 100-microg/actuation strengths was observed for C(max) at both dose levels and for AUC at the higher dose level. The t(1/2) of 17-BMP was found to be approximately 2.8 h.
  
  
  CONCLUSIONS
  This study demonstrated both the strength and dose proportionalities of the BDP extrafine aerosol. This important information will allow physicians maximum flexibility in prescribing this aerosol product.
authors.affiliation: Research and Development Laboratory, 3M Center Building 270-3S-05, 3M Pharmaceuticals, St. Paul, MN, 55144, USA. liharrison@mmm.com
authors.forename: Lester I
authors.initials: LI
authors.lastname: Harrison
authors.forename: Sarala
authors.initials: S
authors.lastname: Kurup
authors.forename: Craig
authors.initials: C
authors.lastname: Wagner
authors.forename: Bruce P
authors.initials: BP
authors.lastname: Ekholm
authors.forename: Julie S
authors.initials: JS
authors.lastname: Larson
authors.forename: Harold B
authors.initials: HB
authors.lastname: Kaiser
mesh_terms: D000328:Adult; D000336:Aerosols; D000368:Aged; D018927:Anti-Asthmatic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D019540:Area Under Curve; D001249:Asthma / Q000188:drug therapy*; D001507:Beclomethasone / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000097:blood / Q000493:pharmacokinetics* / Q000627:therapeutic use*; D018592:Cross-Over Studies; D004305:Dose-Response Relationship, Drug; D005260:Female; D006207:Half-Life; D006801:Humans; D008297:Male; D008875:Middle Aged
chemical_list: D000336:Aerosols; D018927:Anti-Asthmatic Agents; C065857:beclomethasone 17-monopropionate; D001507:Beclomethasone